drugset
drugset / Trial / NCT01872182

Efficacy and Safety Study of ALS-L1023 in Patients With Abdominal Obesity of Metabolic Syndrome

NCT01872182 ↗

Phase 3 Terminated 200 enrolled Hanmi Pharmaceutical Company Limited
RandomizedParallel-groupDouble-blindTreatment

Summary

The main objective of this study is to evaluate efficacy and safety of ALS-L1023 tablet in patients with abdominal obesity of metabolic syndrome.

Timeline

Start
2013-05
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ALS-L1023 Unknown 300 mg —

Indications

abdominal obesity-metabolic syndrome